Profile of darunavir in the management of treatment-experienced HIV patients

Abstract

Cameron Wolfe, Charles HicksDuke University Medical Center, Division of Infectious Diseases, Durham, NC, USAAbstract: Darunavir (formerly TMC114) is a second-generation, sulfonamide-based, peptidomimetic protease inhibitor (PI) with a modified 3-dimensional structure enabling more efficient binding to HIV protease. It has become an important drug, in combination with low-dose ritonavir boosting, in the treatment of both antiretroviral-naïve and multiclass-experienced patients. Growing data now exist suggesting it possesses a high barrier to resistance and requires multiple PI mutations in order to suffer reduced virological potency.Keywords: darunavir, HIV, ritonavir